Skip to search formSkip to main contentSkip to account menu

Fedratinib

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

TG101348

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by either primary myelofibrosis, or secondary MF following… 
2019
2019
Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Na…
Introduction: Cytopenias are a leading cause of ruxolitinib (RUX) discontinuation for patients (pts) with myelofibrosis (MF… 
2019
2019
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason…
Background: Treatment (Tx) options for patients (pts) with MF are limited following RUX failure. Fedratinib (FEDR) is an oral… 
2018
2018
Compositions and methods for treatment of vitiligo
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be… 
2017
2017
Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
Review
2016
Review
2016
Safety considerations when treating myelofibrosis
ABSTRACT Introduction: Myelofibrosis (MF) is a clonal disorder leading to marrow fibrosis, cytopenias and extramedullary… 
2015
2015
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional…
Review
2013
Review
2013
Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF…
![Graphic][1] Background The JAK1/JAK2 inhibitor ruxolitinib (RUX) is approved for treatment of myelofibrosis (MF). However… 
Review
2013
Review
2013
Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
Background We previously reported that patients with MF enrolled in a randomized Phase II study of fedratinib (SAR302503… 
2013
2013
Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide
Background The impact of JAK inhibitor (JAKi) therapy on the natural history of myelofibrosis remains unclear. While a Phase 3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)